Identification of biomarkers for glycaemic deterioration in type 2 diabetes

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Roderick C. Slieker - , Amsterdam University Medical Centers (UMC), Leiden University (Autor:in)
  • Louise A. Donnelly - , University of Dundee (Autor:in)
  • Elina Akalestou - , Imperial College London (Autor:in)
  • Livia Lopez-Noriega - , Imperial College London (Autor:in)
  • Rana Melhem - , University of Montreal (Autor:in)
  • Ayşim Güneş - , University of Montreal (Autor:in)
  • Frederic Abou Azar - , University of Montreal (Autor:in)
  • Alexander Efanov - , Eli Lilly (Autor:in)
  • Eleni Georgiadou - , Imperial College London (Autor:in)
  • Hermine Muniangi-Muhitu - , Imperial College London (Autor:in)
  • Mahsa Sheikh - , Imperial College London (Autor:in)
  • Giuseppe N. Giordano - , Lund University (Autor:in)
  • Mikael Åkerlund - , Lund University (Autor:in)
  • Emma Ahlqvist - , Lund University (Autor:in)
  • Ashfaq Ali - , Novo Nordisk Foundation (Autor:in)
  • Karina Banasik - , Novo Nordisk Foundation Center for Protein Research (Autor:in)
  • Søren Brunak - , Novo Nordisk Foundation Center for Protein Research (Autor:in)
  • Marko Barovic - , Institut für Klinische Chemie und Laboratoriumsmedizin, Technische Universität Dresden (Autor:in)
  • Gerard A. Bouland - , Leiden University (Autor:in)
  • Frédéric Burdet - , Swiss Institute of Bioinformatics (Autor:in)
  • Mickaël Canouil - , Université de Lille (Autor:in)
  • Iulian Dragan - , Swiss Institute of Bioinformatics (Autor:in)
  • Petra J.M. Elders - , Amsterdam University Medical Centers (UMC) (Autor:in)
  • Celine Fernandez - , Lund University (Autor:in)
  • Andreas Festa - , Eli Lilly Regional Operations GmbH, LK Stockerau (Autor:in)
  • Hugo Fitipaldi - , Lund University (Autor:in)
  • Phillippe Froguel - , Université de Lille, Imperial College London (Autor:in)
  • Valborg Gudmundsdottir - , University of Iceland, Icelandic Heart Association (Autor:in)
  • Vilmundur Gudnason - , University of Iceland, Icelandic Heart Association (Autor:in)
  • Mathias J. Gerl - , Lipotype GmbH (Autor:in)
  • Amber A. van der Heijden - , Amsterdam University Medical Centers (UMC) (Autor:in)
  • Lori L. Jennings - , Novartis USA (Autor:in)
  • Michael K. Hansen - , Johnson & Johnson (Autor:in)
  • Min Kim - , Novo Nordisk Foundation, King's College London (KCL) (Autor:in)
  • Isabelle Leclerc - , Imperial College London, University of Montreal (Autor:in)
  • Christian Klose - , Lipotype GmbH (Autor:in)
  • Dmitry Kuznetsov - , Swiss Institute of Bioinformatics (Autor:in)
  • Dina Mansour Aly - , Lund University (Autor:in)
  • Florence Mehl - , Swiss Institute of Bioinformatics (Autor:in)
  • Diana Marek - , Swiss Institute of Bioinformatics (Autor:in)
  • Olle Melander - , Lund University (Autor:in)
  • Anne Niknejad - , Swiss Institute of Bioinformatics (Autor:in)
  • Filip Ottosson - , Lund University, Statens Serum Institut (Autor:in)
  • Imre Pavo - , Eli Lilly Regional Operations GmbH (Autor:in)
  • Kevin Duffin - , Eli Lilly (Autor:in)
  • Samreen K. Syed - , Eli Lilly (Autor:in)
  • Janice L. Shaw - , Eli Lilly (Autor:in)
  • Over Cabrera - , Eli Lilly (Autor:in)
  • Timothy J. Pullen - , Imperial College London, King's College London (KCL) (Autor:in)
  • Kai Simons - , Lipotype GmbH (Autor:in)
  • Michele Solimena - , Molekulare Diabetologie, Technische Universität Dresden (Autor:in)
  • Tommi Suvitaival - , Novo Nordisk Foundation (Autor:in)
  • Asger Wretlind - , Novo Nordisk Foundation (Autor:in)
  • Peter Rossing - , Novo Nordisk Foundation, Universität Kopenhagen (Autor:in)
  • Valeriya Lyssenko - , University of Bergen, Lund University (Autor:in)
  • Cristina Legido Quigley - , Novo Nordisk Foundation, King's College London (KCL) (Autor:in)
  • Leif Groop - , Lund University, University of Helsinki (Autor:in)
  • Bernard Thorens - , Université de Lausanne (Autor:in)
  • Paul W. Franks - , Lund University, Harvard University (Autor:in)
  • Gareth E. Lim - , University of Montreal (Autor:in)
  • Jennifer Estall - , University of Montreal (Autor:in)
  • Mark Ibberson - , Swiss Institute of Bioinformatics (Autor:in)
  • Joline W.J. Beulens - , Amsterdam University Medical Centers (UMC), Utrecht University (Autor:in)
  • Leen M. ’t Hart - , Amsterdam University Medical Centers (UMC), Leiden University (Autor:in)
  • Ewan R. Pearson - , University of Dundee (Autor:in)
  • Guy A. Rutter - , Imperial College London, University of Montreal, Lee Kong Chian School of Medicine (Autor:in)

Abstract

We identify biomarkers for disease progression in three type 2 diabetes cohorts encompassing 2,973 individuals across three molecular classes, metabolites, lipids and proteins. Homocitrulline, isoleucine and 2-aminoadipic acid, eight triacylglycerol species, and lowered sphingomyelin 42:2;2 levels are predictive of faster progression towards insulin requirement. Of ~1,300 proteins examined in two cohorts, levels of GDF15/MIC-1, IL-18Ra, CRELD1, NogoR, FAS, and ENPP7 are associated with faster progression, whilst SMAC/DIABLO, SPOCK1 and HEMK2 predict lower progression rates. In an external replication, proteins and lipids are associated with diabetes incidence and prevalence. NogoR/RTN4R injection improved glucose tolerance in high fat-fed male mice but impaired it in male db/db mice. High NogoR levels led to islet cell apoptosis, and IL-18R antagonised inflammatory IL-18 signalling towards nuclear factor kappa-B in vitro. This comprehensive, multi-disciplinary approach thus identifies biomarkers with potential prognostic utility, provides evidence for possible disease mechanisms, and identifies potential therapeutic avenues to slow diabetes progression.

Details

OriginalspracheEnglisch
Aufsatznummer2533
FachzeitschriftNature communications
Jahrgang14
Ausgabenummer1
PublikationsstatusVeröffentlicht - Dez. 2023
Peer-Review-StatusJa

Externe IDs

PubMed 37137910

Schlagworte

Ziele für nachhaltige Entwicklung

Schlagwörter

  • Mice, Animals, Male, Diabetes Mellitus, Type 2/metabolism, Blood Glucose/metabolism, Islets of Langerhans/metabolism, Insulin/metabolism, Lipids, Biomarkers/metabolism, Cell Adhesion Molecules/metabolism, Extracellular Matrix Proteins/metabolism